European Commission Grants Marketing Authorizations for AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for the Treatment of Chronic Hepatitis C
Amgen Presents New Data Supporting First-Line Use Of Vectibix® (Panitumumab) In Combination With FOLFOX In Patients With Wild-Type RAS Metastatic Colorectal Cancer
Exploratory Analysis of Phase 2 Trial Shows Earlier and Sustained Responses in Patients Treated With Vectibix Versus Bevacizumab
Janssen Pharmaceuticals, Inc. Announces Definitive Agreement to Divest U.S. License Rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) extended-release tablets and NUCYNTA® (tapentadol) Oral Solution
TITUSVILLE, N.J., Jan. 15, 2015 /PRNewswire/ -- Janssen Pharmaceuticals, Inc.
Depomed to Acquire U.S. Rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) extended release tablets and NUCYNTA® (tapentadol) Oral Solution from Janssen Pharmaceuticals, Inc. for $1.05 billion
Vince & Associates Clinical Research Joins Cardiac Safety Research Consortium
Vince & Associates Clinical Research
Overland Park, Kansas - Vince & Associates Clinical Research announced today its membership into the Cardiac Safety Research Consortium (CSRC). As a member of the CSRC, Vince & Associates...
Boehringer Ingelheim and Sanofi enter into a strategic contract manufacturing alliance to produce biopharmaceuticals
Human Longevity, Inc. Signs Agreement with Genentech for Whole Genome Sequencing and Analysis of Samples
LA JOLLA, Calif., Jan. 14, 2015 /PRNewswire/ -- Human Longevity, Inc.
Seattle Genetics and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate Combination of Adcetris® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Hematologic Malignancies
Portola Pharmaceuticals Initiates Phase 4 Study to Support Accelerated Approval of Andexanet Alfa -- Its Breakthrough-Designated Factor Xa Inhibitor Antidote
Thermo Fisher Scientific Releases New CE-IVD Tumor Panel for Next Generation Sequencing
Media:Thermo Fisher ScientificSuzanne Clancy, 760-602-4545
NHS increases budget for cancer drugs fund from £280 million in 2014/15 to an expected £340 million in 2015/16
MD Anderson's Moon Shots Program key to Collaboration
THOUSAND OAKS, Calif. and HOUSTON,